Developing differentiated treatment options that address global unmet needs in multi-billion dollar markets
review our transforming drug-delivery platforms
Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
Virpax’s transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to enhance compliance and to optimize the efficacy of our non-addictive pain management pipeline and our Central Nervous System (CNS) disorder pipeline.
Virpax’s non-addictive pain management pipeline is being developed to provide prescribers more treatment options to help individualized patient care. Once approved, these pain management alternatives may help patients achieve better health outcomes.
Virpax is traded on
(Nasdaq: VRPX)
View our presentation
OPTIMIZING NON-ADDICTIVE DRUG DELIVERY
IN THE TREATMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES
Envelta™
Molecular Envelope Enkephalin Powder
Envelta is a patented intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
Recent Press Releases
March 22, 2023
Recent Media
OUR MISSION
Our mission is to use our proprietary delivery platforms to optimize the efficacy of our non-addictive post operative pain, severe pain and CNS disorder product candidates.
We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide, including rare and orphan diseases.
